Loading organizations...
§ Private Profile · South San Francisco, CA, USA
NewLimit is a technology company.
NewLimit develops epigenetic reprogramming medicines designed to treat age-related diseases, with the ultimate goal of extending human healthspan. The company's technical approach involves a deep interrogation of epigenetic drivers of aging, leveraging primary human cells and reference species to construct sophisticated machine learning models. This methodology aims to identify and understand chromatin features that change with age, and subsequently develop therapies to slow, halt, or potentially reverse these aging processes.
NewLimit was co-founded in 2021 by Brian Armstrong and Blake Byers, with Jacob Kimmel also serving as a co-founder and President. The founding insight stemmed from the growing understanding of cellular plasticity, specifically the ability to reprogram cells, combined with advancements in biological tools. The founders bring a blend of experience in building successful companies across both software and biological domains, recognizing the immense potential to apply industrial-scale efforts to aging research.
The company focuses on specific patient populations suffering from age-related diseases with significant unmet medical needs. NewLimit's long-term vision is to restore the regenerative potential lost during aging, thereby improving quality of life and alleviating suffering. The ambition is to make these advanced longevity therapies widely accessible over time, moving beyond initial breakthroughs to broad public benefit.
NewLimit has raised $347.0M across 4 funding rounds.
NewLimit has raised $347.0M in total across 4 funding rounds.
NewLimit has raised $347.0M across 4 funding rounds. Most recently, it raised $45.0M Other Equity in October 2025.
NewLimit has raised $347.0M in total across 4 funding rounds.
NewLimit's investors include Duke University, Eli Lilly and Company, Section 32, Kleiner Perkins, 8VC, Afore Capital, Andreessen Horowitz, C2 Investment, Caffeinated Capital, Cambrian Ventures, Cubit Capital, General Catalyst.
NewLimit is a biotechnology company founded in 2022 that develops epigenetic reprogramming therapies to restore youthful function in aging cells, targeting age-related diseases in the liver, immune, and vascular systems as a path to extending human healthspan.[1][2][3] The company serves patients with unmet needs in aging-related conditions by inventing RNA-based medicines discovered through AI models, single-cell genomics, and functional assays, addressing the functional decline in specific cell types like hepatocytes, T cells, and endothelial cells.[2][3] With 34-43 employees (over 90% in technical roles as of May 2025) and $202.2 million raised across Series A ($40M) and Series B ($130M at $810M valuation), NewLimit demonstrates strong growth momentum, advancing liver mRNA medicines toward clinical trials while scaling research.[1][2]
NewLimit was co-founded in 2022 by Blake Byers, Brian Armstrong (Coinbase co-founder), and Jacob Kimmel, all with deep expertise in biotech, AI, and entrepreneurship, headquartered in South San Francisco, California.[1][2] The idea emerged from advances in epigenetic control of gene expression, aiming to reverse age-related cellular decline by reprogramming old cells to act young via transcription factor combinations delivered as RNA medicines.[2][3] Early traction included an initial funding commitment, followed by a 2023 $40M Series A from Dimension, Founders Fund, Kleiner Perkins, and angels, then a $130M Series B to push programs into clinical development, reflecting rapid validation of their vision.[1][2]
NewLimit rides the convergence of AI, genomics, and longevity biotech, capitalizing on breakthroughs in epigenetic reprogramming to treat aging as a programmable disease rather than inevitable decline.[2][3] Timing is ideal amid surging investor interest in healthspan extension—evidenced by their $810M Series B valuation—and market forces like aging populations, AI-driven drug discovery acceleration, and mRNA tech maturation post-COVID.[1] By pioneering cell-type-specific therapies, NewLimit influences the ecosystem, validating AI-biotech fusion (e.g., for liver and immune rejuvenation) and paving the way for competitors while attracting talent to the field.[1][2][3][4]
NewLimit is poised to advance its lead liver mRNA programs into clinical trials, expand multi-cell-type pipelines, and hire aggressively to hit 20-year healthspan goals, fueled by Series B capital.[1][2] Trends like AI-optimized therapeutics and regulatory shifts toward aging biology will accelerate progress, potentially evolving their influence from niche innovator to longevity category leader. This positions them to redefine medicine, turning cellular aging reversal from sci-fi to standard care—echoing their mission to extend healthy human life.[3]